Acute Myeloid Leukemia (non-APL) · Venetoclax + Azacitidine (AML, unfit) — VIALE-A schedule

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-VEN-AZA-AML`

ID	`IND-AML-1L-VEN-AZA`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-ELN-AML-2022` `SRC-NCCN-AML-2025` `SRC-VIALE-A-DINARDO-2020`

Notes

Standard track for AML 1L unfit. Curative potential limited (median OS ~14 months); a subset (~25-30%) achieves durable remission lasting 1-3 years. AlloHCT generally off the table for this group, though CR1 → reduced-intensity conditioning alloHCT is occasionally pursued in borderline cases. STUB — requires clinical co-lead signoff.

Used By

Algorithms

ALGO-AML-1L - ALGO-AML-1L
ALGO-AML-2L - ALGO-AML-2L